The overall goal of this proposal is to develop novel immunotherapeutic strategies for the elimination of specific pathogenic T cells. The central premise of the investigators is that cell based immunotherapies can be devised that are specific and effective. This premise, and the specifics of their approach, are based upon a series of findings relating to the molecular mechanisms of immunoregulation mediated by CD8+ lymphocytes. These findings, based primarily on anti-sense and sense mutagenesis experiments that allow a fine dissection of surface molecular phenotypes, have permitted them to formulate an integrated hypothesis with the following tenets: 1) Immunoregulation can occur through cell:cell contact; 2) Cell surface-associated molecules mediate immunoregulatory signaling in this cellular contact based mode of immunoregulation; 3) Cosignaling is the operative mechanism for this type of immunoregulation (paralleling the well established cosignalling mechanism that is operative in immune cell activation); and 4) In the case of CD8+ immunoregulatory cells, the cosignaling consists of two defined components. One is the specific cell surface associated antigen. The second is the nonspecific cosignal, cell surface associated CD8alpha. This hypothesis defines a new function for CD8alpha.Namely, this well known receptor/adhesion molecule, capable of receiving activating signals, can also function as a ligand molecule, sending inhibitory signals. They now seek to use this property of CD8 to develop novel CD8 based therapies to effect antigen specific immunoregulation. A byproduct of these investigations may be insights into the physiological relevance of antigen-specific CD8-dependent immunoregulation.
Specific Aims #1 and #2 are directed toward the design of engineered CD8alpha polypeptide derivatives that can be used to coat primary antigen presenting cells and that have immunotherapeutic potential.
Specific Aims #3, #4 and #5 are directed toward defining, at a molecular level, the inhibitory mechanisms in target cells undergoing antigen specific CD8 dependent immunoregulation.
Specific Aim #5 seeks to develop animal model systems for the evaluation of antigen specific CD8 dependent immunotherapeutics and mechanisms.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI031044-03
Application #
2066031
Study Section
Pathology A Study Section (PTHA)
Project Start
1992-07-01
Project End
1997-04-30
Budget Start
1994-05-01
Budget End
1995-04-30
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Pathology
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Razmara, Marjaneh; Hilliard, Brendan; Ziarani, Azadeh K et al. (2009) Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis. Am J Pathol 174:460-74
Razmara, Marjaneh; Hilliard, Brendan; Ziarani, Azadeh K et al. (2008) CTLA-4 x Ig converts naive CD4+CD25- T cells into CD4+CD25+ regulatory T cells. Int Immunol 20:471-83
Orbach, Ariel; Rachmilewitz, Jacob; Parnas, Miram et al. (2007) CTLA-4 . FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals. J Immunol 179:7287-94
Tone, Yukiko; Kojima, Yoshitsugu; Furuuchi, Keiji et al. (2007) OX40 gene expression is up-regulated by chromatin remodeling in its promoter region containing Sp1/Sp3, YY1, and NF-kappa B binding sites. J Immunol 179:1760-7
Dranitzki-Elhalel, M; Huang, J H; Sasson, M et al. (2007) CD40.FasL inhibits human T cells: evidence for an auto-inhibitory loop-back mechanism. Int Immunol 19:355-63
Chen, Aoshuang; Zheng, Guoxing; Tykocinski, Mark L (2003) Quantitative interplay between activating and pro-apoptotic signals dictates T cell responses. Cell Immunol 221:128-37
Elhalel, Michal Dranitzki; Huang, Jui-Han; Schmidt, William et al. (2003) CTLA-4. FasL induces alloantigen-specific hyporesponsiveness. J Immunol 170:5842-50
Tykocinski, Mark L; Chen, Aoshuang; Huang, Jui-Han et al. (2003) New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints. Immunol Res 27:565-74
Moody, D Branch; Briken, Volker; Cheng, Tan-Yun et al. (2002) Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation. Nat Immunol 3:435-42
Zheng, G; Chen, A; Sterner, R E et al. (2001) Induction of antitumor immunity via intratumoral tetra-costimulator protein transfer. Cancer Res 61:8127-34

Showing the most recent 10 out of 24 publications